Abstract: The present invention relates to fatty acid esters of polyols or sulfonated fatty acid esters or sulfonated fatty acid amides containing at least one group Y, where Y stands for CF3—(CH2)a—O—, SF5—, CF3—(CH2)a—S—, CF3CF2S—, [CF3—(CH2)a]2N— or [CF3—(CH2)a]NH—, where a stands for an integer selected from the range from 0 to 5, or formula (I), where Rf stands for CF3—(CH2)r—, CF3—(CH2)r—O—, CF3—(CH2)r—S—, CF3CF2—S—, SF5—(CH2)t— or [CF3—(CH2)r]2N—, [CF3—(CH2)r]NH— or (CF3)2N—(CH2)r—, B stands for a single bond, O, NH, NR, CH2, C(O)—O, C(O), S, CH2—O, O—C(O), N—C(O), C(O)—N, O—C(O)—N, N—C(O)—N, O—SO2 or SO2—O, R stands for alkyl having 1 to 4 C atoms, b stands for 0 or 1 and c stands for 0 or 1, q stands for 0 or 1, where at least one radical from b and q stands for 1, and r stands for 0, 1, 2, 3, 4 or 5, to processes for the preparation of these compounds, and to uses of these surface-active compounds.

Abstract: The invention provides a method of sustained delivery of a tertiary amine-containing parent drug comprising administering to a patient an effective amount of a prodrug compound of the invention wherein upon administration to the patient, release of the parent drug from the prodrug is sustained release. Prodrug compounds suitable for use in the methods of the invention are labile quaternary ammonium salts of tertiary amine-containing parent drugs (or tertiary imine-containing parent drugs) that are derivatized through aldehyde-linked prodrug moieties that reduce the solubility of the prodrug compound at a reference pH as compared to the parent drug. The physical, chemical and solubility properties of these derivatives can be further modulated by the choice of counterion X?. In one embodiment, the present invention provides a prodrug compound of Formula I: where R1-R5 are defined in the written description of the invention.

Abstract: A method of increasing the fluorous nature of a compound includes the step of reacting the compound with at least one second compound having the formula: wherein Rf is a fluorous group, Rs is a spacer group, d is 1 or 0, m is 1, 2 or 3, Ra is an alkyl group and X is a suitable leaving group. A compound has the formula: wherein Rf is a fluorous group, n is an integer between 0 and 6, m is 1, 2 or 3, Ra is an alkyl group and X is a leaving group.

Abstract: The present invention relates to novel modified fatty acid analogs, where a positron or gamma-emitting label is placed at a position on a fatty acid backbone and an organic substituent is substituted at the 2,3; 3,4; 4,5; 5,6 and other sequence positions of a fatty acid backbone. These novel fatty acid analogs are designed to enter the tissues of interest by the same long chain fatty acid carrier mechanism as natural fatty acids, however, functional substituents in the 2,3; 3,4; 4,5; 5,6 and other sequence positions, block the catabolic pathway, thus trapping these analogs in a virtually unmodified form in the tissues of interest.

Abstract: The present invention relates to a novel process for producing a &dgr;-lactone of the formula: 1

Abstract: Perfluorinated esters of alkanoyl-L-carnitine of the formula (I): are useful as cationic lipids for the intracellular delivery of pharmacologically active compounds.

Abstract: Fluorinated diesters useful for imparting repellency of low surface tension fluids to thermoplastic polymers of formulaeR.sub.f --O--C(O)--(CH.sub.2).sub.n --C(O)--O--R.sub.1 ;R.sub.f --O--C(O)--CH.sub.2 --CH(R.sub.2)--C(O)--O--R.sub.f ;a mixture of R.sub.f --O--C(O)--(CH.sub.2).sub.n --C(O)--O--R.sub.1,R.sub.f --O--C(O)--(CH.sub.2).sub.n --C(O)--R.sub.f, and R.sub.1 --O--C(O)--(CH.sub.2).sub.n --C(O)--O--R.sub.1 ;and [F(CF.sub.2).sub.x CH.sub.2 CH.sub.2 --S--CH.sub.2 ].sub.2 --C--[CH.sub.2 --O--C(O)--C.sub.17 H.sub.35 ].sub.2 ;wherein R.sub.f is F(CF.sub.2).sub.x --(CH.sub.2).sub.m wherein x is 4 to 20 and m is 2 to 6, or F(CF.sub.2).sub.x --SO.sub.2 N(R.sub.3)--R.sub.4 wherein x is 4 to 20; R.sub.1 is a saturated aliphatic hydrocarbon with an average carbon chain length of 12 to 66 carbons; R.sub.2 is a saturated or unsaturated hydrocarbon with 1-20 carbon atoms; R.sub.3 is an alkyl radical having 1 to 4 carbon atoms; R.sub.

Abstract: For use in transporting biologically active species into and through membrane barriers, a cationic amine compound is utilized that has the general structure: ##STR1## wherein R.sub.4 and R.sub.5 are a pair of same or different lipoyl moieties selected from a group consisting of an alkyl, alkenyl, alkynyl, alkanoyl, alkenoyl, or alkynoyl groups and for R.sub.1 R.sub.2, and R.sub.3 at least two are hydroxylated, ether containing, or acyloxy containing alkyl, alkenyl, or alkynyl groups or at least one amine bonded halogen containing moiety selected from a group consisting of a halogenated alkyl, alkenyl, or alkynyl group or a mixture of at least one halogen containing moiety selected from a group consisting of a halogenated alkyl, alkenyl, or alkynyl group and at least one hydroxylated, ether containing, or acyloxy containing alkyl, alkenyl, or alkynyl group, and X.sup.- is an anion.

Abstract: Acyl chlorides are prepared by reacting a carboxylic acid or its anhydride with carbonyl chloride in the presence of a carboxamide of the formula I ##STR1## where R.sup.1 is a radical of the formula ##STR2## R.sup.2 and R.sup.3 are each alkyl of 1 to 9 carbon atoms, R.sup.4 and R.sup.5 are each hydrogen or alkyl of 1 to 9 carbon atoms and the two radicals R.sup.1 and R.sup.2 may furthermore be a hydrocarbon radical which completes the moiety ##STR3## to form a heterocyclic structure, and the stated alkyl and hydrocarbon radicals may furthermore contain substituents which are inert under the reaction conditions.

Abstract: Compounds of the formula ##STR1## wherein R.sub.1, R.sub.2, R.sub.3 and R.sub.4 independently are hydrogen, lower alkyl of 1 to 6 carbons, halogen or lower alkoxy of 1 to 6 carbons; R.sub.5 and R.sub.5 ' independently are hydrogen or lower alkyl of 1 to 6 carbons; Y is oxygen or sulfur; Z is n-alkyl having 2 to 10 carbons, cyclo or branch-chained alkyl of 3 to 10 carbons, and straight chain alkenyl having 2 to 10 carbons, or cyclo or branched chained alkenyl of 3 to 10 carbons, and the Z-Y substituent is in a 1,2 (ortho) or 1,3 (meta) position on the phenyl ring relative to the ethene moiety; A is (CH.sub.2).sub.n where n is 0-5, lower branched chain alkyl having 3 to 6 carbons, cycloalkyl having 3 to 6 carbons, alkenyl having 2 to 6 carbons and 1 or 2 double bonds, alkynyl having 2 to 6 carbons and 1 or 2 triple bonds; B is COOH or a pharmaceutically acceptable salt thereof, COOR.sub.8, CONR.sub.9 R.sub.10, --CH.sub.2 OH, CH.sub.2 OR.sub.11, CH.sub.2 OCOR.sub.11, CHO, CH(OR.sub.12).sub.2, CHOR.sub.

Abstract: The invention is concerned with a process for preparing a C.sub.6 to C.sub.24 fatty acid halide by reacting a fatty acid with a halogenating agent, such as phosphorus trichloride, optionally followed by hydrolysis of unreacted halogenating agent separating and removing an inorganic lower layer to leave a turbid layer containing the fatty acid chloride product. The clearing time of the turbid layer is reduced by the addition of from 3 to 20% by weight of clear fatty acid halide thereto.

Abstract: A process for preparing carbonyl chlorides of the formula I ##STR1## where R is C.sub.1 -C.sub.30 -alkyl, C.sub.2 -C.sub.30 -alkenyl or C.sub.2 -C.sub.30 -alkynyl, from essentially equimolar amounts of a carboxylic acid of the formula II ##STR2## where R has the abovementioned meanings, and phosgene COCl.sub.2 (III), in the presence of a catalytic adduct of phosgene and N,N-disubstituted formamide or the hydrochlorides thereof, of the formula IV where R.sup.1 and R.sup.2 are each, independently of one another, C.sub.1 -C.sub.3 -alkyl or together are a C.sub.4 -C.sub.5 -alkylene chain which may be interrupted by oxygen or by nitrogen which carries C.sub.1 -C.sub.3 -alkyl or CHO, and n is 0, 1 or 2, wherein the reaction is carried out with a stationary phase of the catalytic adduct, is described.

Abstract: A fluorine-containing .alpha.,.omega.-bifunctional compound having the formula: ##STR1## wherein each of R.sup.1 and R.sup.2 independently is a hydrogen atom, an alkyl group or an aralkyl group; X is --COOH, --COOR.sup.3, --COY or --NCO, wherein R.sup.3 is an alkyl group or an aralkyl group and Y is a halogen atom or N.sub.3 ; and n is an integer of at least 1 provided that when X is --COOH, n is an integer of at least 4.